Brian Goff

Brian Goff joined Agios as chief executive officer and a member of the board of directors in August 2022. He has more than 30 years of experience in the biopharmaceutical industry, and for the past 10 years has been an executive global leader focused on rare diseases. Previously, he was executive vice president, and chief commercial and global operations officer of Alexion Pharmaceuticals until its acquisition by AstraZeneca in 2021. In this role, he led worldwide commercial and country operations as well as a global manufacturing and product supply. Prior to joining Alexion in June 2017, Mr. Goff was a chief operating officer and a member of the board of directors of Neurovance, a venture-backed company acquired by Otsuka Pharmaceuticals in 2017. Prior to joining Neurovance, Mr. Goff served as Baxalta’s executive vice president and president of the hematology division until Shire Pharmaceuticals acquired Baxalta in 2016. He previously served with Baxter Healthcare Corporation as global hemophilia franchise head. Earlier in his career, Mr. Goff held positions of increasing responsibility in sales and marketing roles in both the U.S. and in Europe with Novartis Pharmaceuticals. Mr. Goff began his career and served nearly 14 years in the pharmaceutical division of Johnson & Johnson.

In 2014, while at Baxter, Mr. Goff was named ‘Mentor of the Year by the Healthcare Businesswomen’s Association (HBA) in recognition of his long-standing and well-known commitment to diversity. He has served on the advisory boards of BIO, HBA, and Life Science Cares. Mr. Goff has an MBA from the Wharton School at the University of Pennsylvania and a Bachelor of Arts, Phi Beta Kappa, from Skidmore College.